Even though it is Thursday, sometimes it doesn’t hurt to shut things down for the weekend and take a couple days to catch your breath. Sure, there are two more trading days left in the week, but sometimes it doesn’t hurt to do some research and keep your head down. Maybe, going into next week at full steam might pay off better for you then taking a stab in the dark at stocks you might not be fully informed on.
During these next several days before Monday, I suggest spending your time doing research. That could be something as simple as looking at tweets from companies. Pouring through press releases is another option. Why don’t you check out calendars that immense amount of study materials you can find online? Or, you can look through charts until your heart is content. The point is this: you have time, spend it doing something to prepare yourself to pull the trigger next week if the right penny stock profile presents itself.
Some say that “knowing” is truly half the battle. Over the past several weeks, we’ve seen a multitude of penny stocks go on breakout runs. Even though the markets appear volatile on a daily basis, there have been opportunities to make out like a bandit. That said, those who have taken advantage have been well informed and have done their studying. Below, I’ve given you 3 potential-filled ideas to look at and get on your watch-list.
Your New No. 1 Penny Stock To Get On Your Watch-list: PhaseBio Pharmaceuticals, Inc.
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases. The company’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; PB1046, a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension and acute respiratory distress syndrome; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide (ELP) technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including PB1046, and drives both internal and partnership drug-development opportunities.
PhaseBio Pharmaceuticals, Inc. announced FDA authorization to proceed with VANGARD, a potentially pivotal clinical trial to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS).
PB1046 is a novel, once-weekly, subcutaneously-injected vasoactive intestinal peptide (VIP) receptor agonist that targets VPAC receptors in the cardiovascular, pulmonary and immune systems. VIP is a neurohormone known to have anti-inflammatory, antifibrotic, inotropic, lusitropic and vasodilatory effects and several cardiopulmonary disorders are associated with alterations in levels of VIP or its receptors, VPAC1 and VPAC2. Importantly, VIP has also been observed to have potent bronchodilatory and immunomodulatory effects in the respiratory system. Specifically, VIP has been shown to regulate proinflammatory cytokines including TNF-α, IFN-γ, IL-12, IL-17A and IL-6. In animal models, treatment with VIP peptide prevented acute lung injury and inhibited cytokine-mediated inflammatory responses that are characteristic of ARDS.
“Based on the mechanism of action, the well-documented clinical profile of PB1046, a once-weekly-dosing regimen that eliminates the need for continuous IV infusions required to administer VIP peptide, and evidence of activity of VIP peptide in ARDS, we decided to pursue a rigorous, double-blind randomized trial to evaluate PB1046 as a treatment for COVID-19 patients at high risk of progressing to acute respiratory distress syndrome,” said Jonathan Mow, Chief Executive Officer at PhaseBio. “PhaseBio moved very rapidly to develop a study protocol and submit an investigational new drug application (IND) to the FDA. I would like to thank the team at PhaseBio, our network of advisors and investigators and the FDA for the collaborative effort to launch this trial in such an expedited manner.”
Your New No. 2 Penny Stock To Get On Your Watch-list: Hexindai Inc.
Hexindai Inc. (Nasdaq: HX) (“Hexindai” or the “Company”) is a fast-growing consumer lending marketplace based in Beijing, China facilitating loans to meet the increasing consumption needs of underserved prime borrowers in China. Hexindai provides borrowers with convenient and ready access to comprehensive consumer finance services. Hexindai’s strong user acquisition capabilities, cutting-edge risk management system, and strategic relationships with respected financial institutions allow the Company to generate higher customer satisfaction, reliance, and realize fast growth.
Hexindai Inc. announced that it has launched Xiaobai Maimai, a membership-based social e-commerce mobile platform offering high-quality and affordable branded products.
Xiaobai Maimai leverages the Company’s integrated buyer resources to select and source goods globally. Xiaobai Maimai deploys a membership rating system that rewards users with a commission for every purchase, share or recommendation of a product made to friends. The app offers a wide variety of high-quality products in the household goods, food and drinks, and luxury categories.
Mr. Xiaobo An, Founder, Chairman and Chief Executive Officer of Hexindai, commented: “We launched Xiaobai Maimai to diversify our revenue streams and deepen the transformation of our business. We believe social e-commerce has enormous growth potential as consumer behavior increasingly shifts from offline to online purchases and demand grows from China’s emerging middle class. By integrating our extensive buyer resources from all over the world, we are able to source a diverse array of superior high-quality products at competitive prices. Xiaobai Maimai is directly supported by a dedicated operations team focused on enhancing the user experience and a customer service team which offers concierge-level services to our members. This allows us to guarantee product quality and offer a personalized customer experience, which in-turn drives the sharing and recommendation of our products and services. This social e-commerce model not only benefits customers with commissions for shopping and sharing products, but also helps reduce marketing expenses. Leveraging our strong user acquisition capabilities and deep experience in managing online and offline operations, Xiaobai Maimai will position us to further drive the transformation of our business and support sustainable growth going forward.”
Your New No. 3 Penny Stock To Get On Your Watch-list: Aerpio Pharmaceuticals, Inc.
Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO) is a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications. Recently published mouse and human genetic data implicate the Angpt/Tie2 pathway in maintenance of Schlemm’s canal, a critical component of the conventional outflow tract. The Company’s lead compound, razuprotafib (formerly AKB-9778), a first-in-class small molecule inhibitor of vascular endothelial protein tyrosine phosphatase (“VE-PTP”), is being developed as a potential treatment for open angle glaucoma, and the Company intends to investigate the therapeutic potential of razuprotafib in other indications. The Company is also evaluating development options for ARP-1536, a humanized monoclonal antibody, for its therapeutic potential in the treatment of diabetic vascular complications including nephropathy and diabetic macular edema (“DME”). The Company’s third asset is a bispecific antibody that binds both VEGF and VE-PTP which is designed to inhibit VEGF activation and activate Tie2.
Aerpio Pharmaceuticals, Inc. (“Aerpio”) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an agreement has been reached to evaluate razuprotafib in a new randomized, investigational treatment arm in the I-SPY COVID Trial for the treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19.
Approximately 10-15% of those infected with the highly contagious SARS-CoV2 virus, the cause of COVID-19, develop ARDS with a death rate in the 2-10% range. Nearly 70% of COVID-19 patients admitted to the ICU require ventilation for a mean of 14 days, and over 50% will not survive. The unprecedented rate of SARS-CoV-2 (COVID-19) infection, over 5.6 million world-wide, has already led to more than 350,000 deaths.
The goal of this the I-SPY COVID Trial is to rapidly screen multiple promising agents, in the setting of an adaptive platform trial, for the treatment of critically ill COVID-19 patients to identify agents that will have a high impact on reducing mortality, and the need for as well as duration of, mechanical ventilation.
Preclinical models, large human observational studies, and human genetic studies from leading groups worldwide have independently arrived at the concept that a vascular endothelial receptor, Tie2, may play a pivotal role in the defense against microvascular breach in acute respiratory distress syndrome (ARDS) 1-4. We hypothesize that razuprotafib, a being developed as a first-in-class Tie2 activating compound, will exhibit an acceptable safety profile and show efficacy for the treatment of COVID-19 associated ARDS as a potentially life-saving therapeutic for patients suffering from the devastating respiratory effects of COVID-19.
This study arm will evaluate razuprotafib’s potential to sufficiently stabilize the pulmonary vasculature, in order to slow or prevent the progression of COVID-19 associated pulmonary pathology, decrease the need for ventilator support, and reduce mortality.